Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Jaguar Health, Inc. (NASDAQ:JAGX), a pharmaceutical company with a market capitalization of $4.3 million and significant debt burden of $38.3 million, announced Thursday that it has amended its At the Market Offering Agreement to extend the role of Lucid Capital Markets, LLC as a manager under the agreement. According to a statement in a Securities and Exchange Commission filing, Lucid will continue to serve as a manager alongside Ladenburg Thalmann & Co. Inc. until December 31, 2025, unless further extended by the parties. The extension is effective retrospectively from June 30, 2025.
If the agreement is not amended or extended beyond December 31, 2025, Ladenburg Thalmann will become the sole manager under the arrangement, and Lucid will no longer serve in that capacity.
The company also filed a supplement Thursday with the SEC to its previous prospectus supplement dated May 23, 2024 and the accompanying prospectus dated May 1, 2024, relating to this amendment.
Jaguar Health’s At the Market Offering Agreement was originally entered into on December 10, 2021, and has since been amended several times, most recently including this sixth amendment. The company’s common stock is listed on The Nasdaq Stock Market under the symbol JAGX.
This information is based on a press release statement contained in the company’s Form 8-K filing with the SEC.
In other recent news, Jaguar Health reported a significant boost in net revenue for the second quarter of 2025. The company saw a 35% increase from the previous quarter and a 10% rise compared to the same period last year. Despite these positive revenue figures, Jaguar Health is facing ongoing operational losses, which have been a concern for investors. The company continues to focus on expanding its product pipeline as part of its strategic efforts. These developments have been closely watched by analysts and investors alike, reflecting the challenges and opportunities facing Jaguar Health.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.